论文部分内容阅读
目的:探讨分析血必净联合乌司他丁治疗重症肺部感染的临床疗效。方法:回顾性分析2010年7月至2013年2月我院治疗的135例重症肺部感染患者的临床记录资料。结果:治疗后,治疗组的总有效率为93.48%,高于对照1组、对照2组的77.78%、75%,均具有显著性差异(P<0.05)。和两个对照组相比,治疗后治疗组的IL-6、N等炎性因子水平、肺毛细血管通透性指标均明显下降,肺组织顺应性明显升高,PaO2明显升高,P(A-a)O2明显下降,均具有显著性差异(P<0.05)。结论:血必净联合乌司他丁治疗重症肺部感染的临床疗效显著,具有临床推广应用价值。
Objective: To investigate the clinical efficacy of Xuebijing combined with ulinastatin in the treatment of severe pulmonary infection. Methods: The clinical records of 135 patients with severe pulmonary infection treated in our hospital from July 2010 to February 2013 were retrospectively analyzed. Results: After treatment, the total effective rate of the treatment group was 93.48%, which was significantly higher than that of the control group 1 and 77.78%, 75% of the control group 2 (P <0.05). Compared with the two control groups, the levels of IL-6, N and other inflammatory factors in the treatment group were significantly decreased, pulmonary capillary permeability indicators were significantly decreased, pulmonary compliance was significantly increased, PaO2 was significantly increased, P ( Aa) O2 decreased significantly, both with significant difference (P <0.05). Conclusion: The clinical efficacy of Xuebijing combined with ulinastatin in the treatment of severe pulmonary infection is significant and has clinical value of popularization and application.